India's vaccine production capacity to help humanity in fighting Covid: MEA

India will also help all countries in enhancing their cold chain and storage capacities for the delivery of vaccines

Coronavirus, vaccine, covid, drugs, clinical trials
Press Trust of India New Delhi
2 min read Last Updated : Oct 29 2020 | 9:52 PM IST

India's vaccine production and delivery capacity will be used to help all humanity in fighting the COVID-19 pandemic, and it will also help countries in enhancing their cold chain and storage capacities, the Ministry of External Affairs said on Thursday.

Ministry of External Affairs Spokesperson Anurag Srivastava said that as part of such efforts, India organised two training modules for its neighbouring countries in which about 90 health experts and scientists participated.

"We propose to expand these programmes to include other interested countries," he said at an online media briefing.

"As announced by Prime Minister (Narendra Modi) in his speech to the UN General Assembly last month, India's vaccine production and delivery capacity will be used to help all humanity in fighting the COVID-19 pandemic," Srivastava said.

India will also help all countries in enhancing their cold chain and storage capacities for the delivery of vaccines, he said.

From October 17, a delegation of the concerned departments visited Bangladesh and had fruitful discussions with their Bangladeshi counterparts on the current stage of vaccine development in India and modalities of clinical trials in Bangladesh, Srivastava pointed out.

The concerned officials of the two sides have had a virtual interaction on Myanmar's interest in cooperation on COVID19 vaccines, he said.

"As the situation with respect to vaccine development evolves, the sides will discuss and decide on modalities of cooperation," he said.

"In due course, depending on the trials in India, we propose to expand our cooperation with other countries also in clinical trials and capacity building for vaccine development, production and delivery," he said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineSupply chainMEAIndia

First Published: Oct 29 2020 | 9:31 PM IST

Next Story